Atibuclimab

DB06546InvestigationalProtein Based Therapies

Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

Mechanism: Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Curator reviewed
Primary indication: Investigated for use/treatment in sepsis and septicemia and pneumonia.Curator reviewed
Also known as: IC14, (RECOMBINANT CHIMERIC MAB AGAINST HUMAN CD14) · IMMUNOGLOBULIN G4, ANTI-(HUMAN CD14 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL IC14 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL IC14 .KAPPA.-CHAIN, DIMER
Code names: IC-14

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atibuclimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.